Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
Novo Nordisk: Be Cautious About Buying The Dip
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the pharmaceutical industry.
clinicaltrialsarena5m
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...
BioSpace1h
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
Zacks.com on MSN22h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...
Novo Nordisk CEO Lars Jorgensen blames ‘complex US healthcare system’ for steep Ozempic prices — which Senator Bernie Sanders says may lead to higher insurance …
Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...
US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
Novo Nordisk (NVO): Consistent Growth in Diabetes and Obesity Care
We recently published a list of 10 Stocks with Consistent Growth to Buy. In this article, we are going to take a look at ...
STAT15h
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
Head-to-toe… all the little-known ways ‘Ozempic-style’ fat jabs can boost your health
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.